Autologous stem-cell transplantation

United States Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report 2022-2027 - Cumulative Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 27, 2022
Health, Stem Cells, Acquisition, Decision-making, USD, Strategic management, Market share analysis, Value, Business Growth Fund, COVID-19, Customer support, Growth, Autologous stem-cell transplantation, CAGR, Use, Compound annual growth rate, Autotransplantation, State, Consumer, Retail

The "Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report by Type (Autologous Non-Stem Cells and Autologous Stem Cells), Application, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report by Type (Autologous Non-Stem Cells and Autologous Stem Cells), Application, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The United States Autologous Stem Cell & Non-Stem Cell Based Therapies Market size was estimated at USD 1,111.67 million in 2021, USD 1,338.39 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 16.62% to reach USD 2,797.31 million by 2027.
  • The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report to 2027 - Featuring Antria, Bioheart and Brainstorm Cell Therapeutics Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 12, 2022
Pharmaceutical, Health, Stem Cells, Use, R, Certification, Customer support, Compound annual growth rate, Investment, Business Growth Fund, Strategic management, USD, Decision-making, COVID-19, Autologous stem-cell transplantation, Technology, Market share analysis, CAGR, Acquisition, Growth, Value, Mobile phone, Retail, Fine chemical

What is the market size and forecast of the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?

Key Points: 
  • What is the market size and forecast of the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
  • What is the competitive strategic window for opportunities in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
  • What is the market share of the leading vendors in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
  • What modes and strategic moves are considered suitable for entering the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?

BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Medicine, Clinical medicine, Transplantation medicine, Hematology, Stem cells, Cytokines, Growth factors, Granulocyte colony-stimulating factor, Apheresis, Autologous stem-cell transplantation, Organ transplantation

The addition of Motixafortide to G-CSF also allowed 88.3% of patients to undergo transplantation after only one apheresis session, compared to 10.8% in the G-CSF arm an 8.2-fold increase.

Key Points: 
  • The addition of Motixafortide to G-CSF also allowed 88.3% of patients to undergo transplantation after only one apheresis session, compared to 10.8% in the G-CSF arm an 8.2-fold increase.
  • "This is a great achievement in alleviating the burden for the patients and reducing hospital resources.
  • I believe these results make the combination of Motixafortide and G-CSF a very attractive candidate for use in all patients with multiple myeloma undergoing autologous stem-cell transplantation.
  • "\n"These strikingly positive data significantly exceeded our expectations, and are truly transformational for our company," stated Philip Serlin, Chief Executive Officer of BioLineRx.

Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV

Retrieved on: 
Monday, June 8, 2020
Medical specialties, Medicine, Stem cells, Branches of biology, Transplantation medicine, Hematology, Hematopoietic stem cell transplantation, Lymphology, Surgical oncology, Autologous stem-cell transplantation, Center for Biologics Evaluation and Research, HIV/AIDS

The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01.

Key Points: 
  • The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01.
  • ENOB-HV-01 is a novel approach to autologous stem cell transplantation, with the potential to cure HIV by increasing engraftment of gene-modified cells that are resistant to HIV infection.
  • Failure to achieve engraftment has limited the success of other attempts to cure HIV with autologous transplantation.
  • We considered the meeting to be very successful, with strong alignment between Enochians approach to developing ENOB-HV-01 and the comments of the FDA reviewers, said Dr. Mark Dybul, Executive Vice-Chair of Enochian BioSciences.

Stem Cell Therapy | Global Industry Review 2015-2019 and Forecast to 2025

Retrieved on: 
Wednesday, May 13, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Emerging technologies, Life extension, Stem-cell therapy, Cell therapy, Prochymal, Autologous stem-cell transplantation

The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period.

Key Points: 
  • The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period.
  • Additionally, increase in number of stem cell banks and growing investments by the government and private organizations for the development of stem cell preservation infrastructure is further propelling the market across the globe.
  • The allogenic type segment is expected to register the highest growth during forecast period attributable to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, growing number of clinical trials related to allogeneic stem cell therapies, among others.
  • Regionally, the stem cell therapy market has been segmented into various regions namely Asia-Pacific, North America, South America, Europe, and Middle East & Africa.

Enochian Biosciences Announces FDA INTERACT Meeting for a Potential Cure for HIV

Retrieved on: 
Monday, February 24, 2020
Medical specialties, Medicine, Branches of biology, Transplantation medicine, Stem cells, Biotechnology, Emerging technologies, Molecular biology, Hematopoietic stem cell transplantation, Genetic engineering, Center for Biologics Evaluation and Research, Autologous stem-cell transplantation

FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV.

Key Points: 
  • FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV.
  • INTERACT is the first available FDA interaction and is a key step in the process towards an Investigational New Drug (IND) to study first-in-human products leading to potential marketing approval.
  • LOS ANGELES, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on genetically modified cellular and immune therapy for infectious diseases and cancer, announces that the FDA has scheduled an Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meeting for early June.
  • The meeting is focused on Enochians ENOB-HV-01, a novel approach to autologous stem cell transplantation with the potential to increase engraftment of genetically modified cells that are resistant to HIV infection, as a potential cure for HIV.

BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery

Retrieved on: 
Thursday, August 8, 2019
Branches of biology, Life sciences, Biology, Stem cells, Biotechnology, Cell biology, Cell therapy, Therapy, Autologous stem-cell transplantation, Limbal stem cell

Today, autologous cardiac cell therapy where a patients own cells are used is challenged by patient variation, which makes outcomes unpredictable, and by the high costs associated with manufacturing single-batch therapy remotely for each patient.

Key Points: 
  • Today, autologous cardiac cell therapy where a patients own cells are used is challenged by patient variation, which makes outcomes unpredictable, and by the high costs associated with manufacturing single-batch therapy remotely for each patient.
  • BioCardias new patent addresses a potential solution to these problems a diagnostic approach for patient selection that identifies a specific biomarker signature in a patients bone marrow.
  • Our diagnostic assay is a potential breakthrough in improving outcomes and dramatically reducing costs for autologous cardiac cell therapy, said BioCardia CEO Peter Altman PhD.
  • It also avoids the potential technical hurdles of allogenic cell therapy, using donor cells, which can create risks for patients.